As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works ...

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Drug developers can now leverage large language models to draft regulatory documents, which they hope will shorten the time ...

Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for ...

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

Menopause-related health problems, both physical and mental, have become a pressing issue for women at the transformative age ...

EVM14 is the first messenger RNA (mRNA) therapeutic vaccine developed internally by the company to gain this approval. Its mechanism is designed to improve the efficacy of existin ...

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

CERo Therapeutics (CERO) announces that the Company has received clearance by the U.S. Food and Drug Administration, FDA, for a second ...